Computational drug repositioning: From data to therapeutics

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 4, 2013, Pages 335-341

  Hurle, M R ^a   Yang, L ^a   Xie, Q ^a   Rajpal, D K ^a   Sanseau, P ^b   Agarwal, P ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; LITHIUM; METHOTREXATE; PHENOXYBENZAMINE; SILDENAFIL; TOPIRAMATE; URSOLIC ACID;

ADVERSE DRUG REACTION; AMYOTROPHIC LATERAL SCLEROSIS; ANGINA PECTORIS; ARTHRALGIA; DRUG REPOSITIONING; DRUG SCREENING; DRUG TARGETING; ELECTRONIC MEDICAL RECORD; ERECTILE DYSFUNCTION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DATABASE; GENOME ANALYSIS; GRAFT REJECTION; HUMAN; IN VIVO STUDY; MATHEMATICAL ANALYSIS; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; OSTEOARTHRITIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOCIAL MEDIA; TRANSCRIPTOMICS; UNSPECIFIED SIDE EFFECT;

COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG DISCOVERY; DRUG REPOSITIONING; ELECTRONIC HEALTH RECORDS; HUMANS; TRANSCRIPTOME;

EID: 84875459651     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.1     Document Type: Review

References (64)

1. Achenbach, J., Tiikkainen, P., Franke, L. & Proschak, E. Computational tools for polypharmacology and repurposing. Future Med. Chem. 3, 961-968 (2011).
2. Swinney, D.C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519 (2011).
3. Ashburn, T.T. & Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683 (2004).
4. Aronson, J.K. Old drugs-new uses. Br. J. Clin. Pharmacol. 64, 563-565 (2007).
5. Barratt, M.J., & Frail, D.E. Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. (John Wiley & Sons, Hoboken, NJ, 2012).
6. Gelijns, A.C., Rosenberg, N. & Moskowitz, A.J. Capturing the unexpected benefits of medical research. N. Engl. J. Med. 339, 693-698 (1998).
7. Ladizinski, B., Shannon, E.J., Sanchez, M.R. & Levis, W.R. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J. Drugs Dermatol. 9, 814-826 (2010).
8. Chong, C.R. & Sullivan, D.J. Jr. New uses for old drugs. Nature 448, 645-646 (2007).
9. Ghofrani, H.A., Osterloh, I.H. & Grimminger, F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5, 689-702 (2006).
10. Swanson, D.R. Medical literature as a potential source of new knowledge. Bull. Med. Libr. Assoc. 78, 29-37 (1990).
11. Swanson, D.R. Fish oil, Raynaud's syndrome, and undiscovered public knowledge. Perspect. Biol. Med. 30, 7-18 (1986).
12. Cameron, D. et al. A graph-based recovery and decomposition of Swanson's hypothesis using semantic predications. J. Biomed. Inform. (2012); e-pub ahead of print 28 September 2012.
13. Sanseau, P. & Koehler, J. Editorial: computational methods for drug repurposing. Brief. Bioinformatics 12, 301-302 (2011).
14. Dudley, J.T., Deshpande, T. & Butte, A.J. Exploiting drug-disease relationships for computational drug repositioning. Brief. Bioinformatics 12, 303-311 (2011).
15. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
16. Kunkel, S.D. et al. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab. 13, 627-638 (2011).
17. Dudley, J.T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).
18. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
19. Qu, X.A. & Rajpal, D.K. Applications of connectivity map in drug discovery and development. Drug Discov. Today 17, 1289-1298 (2012).
20. Chang, M., Smith, S., Thorpe, A., Barratt, M.J. & Karim, F. Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. Mol. Pain 6, 56 (2010).
21. Hu, G. & Agarwal, P. Human disease-drug network based on genomic expression profiles. PLoS ONE 4, e6536 (2009).
22. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).
23. I orio, F. et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. USA 107, 14621-14626 (2010).
24. Cheng, J., Xie, Q., Hurle, M., Freudenberg, J.M., Yang, L. & Agarwal, P. Evaluation of analytical methods for Connectivity map data. Pac. Symp. Biocomput. 18, 5-16 (2013).
25. Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S. & Baron, A.D.; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628-2635 (2004).
26. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
27. Duran-Frigola, M. & Aloy, P. Recycling side-effects into clinical markers for drug repositioning. Genome Med. 4, 3 (2012).
28. Yang, L. & Agarwal, P. Systematic drug repositioning based on clinical sideeffects. PLoS ONE 6, e28025 (2011).
29. Cahill, B.C. et al. Methotrexate for lung transplant recipients with steroidresistant acute rejection. J. Heart Lung Transplant. 15, 1130-1137 (1996).
30. Duke, J., Friedlin, J. & Ryan, P. A quantitative analysis of adverse events and "overwarning" in drug labeling. Arch. Intern. Med. 171, 944-946 (2011).
31. Mardis, E.R. The impact of next-generation sequencing technology on genetics. Trends Genet. 24, 133-141 (2008).
32. Bamshad, M.J. et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12, 745-755 (2011).
33. St Hilaire, C. et al. NT5E mutations and arterial calcifications. N. Engl. J. Med. 364, 432-442 (2011).
34. Hindorff, L.A. et al. Potential etiologic and functional implications of genomewide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 106, 9362-9367 (2009).
35. Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010).
36. Sanseau, P. et al. Use of genome-wide association studies for drug repositioning. Nat. Biotechnol. 30, 317-320 (2012).
37. Butte, A.J. & Kohane, I.S. Creation and implications of a phenome-genome network. Nat. Biotechnol. 24, 55-62 (2006).
38. Li, Y. & Agarwal, P. A pathway-based view of human diseases and disease relationships. PLoS ONE 4, e4346 (2009).
39. Suthram, S., Dudley, J.T., Chiang, A.P., Chen, R., Hastie, T.J. & Butte, A.J. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput. Biol. 6, e1000662 (2010).
40. Swamidass, S.J. Mining small-molecule screens to repurpose drugs. Brief. Bioinformatics 12, 327-335 (2011).
41. Skarnes, W.C. et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474, 337-342 (2011).
42. Chiang, A.P. & Butte, A.J. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin. Pharmacol. Ther. 86, 507-510 (2009).
43. Gottlieb, A., Stein, G.Y., Ruppin, E. & Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol. 7, 496 (2011).
44. Wang, Y. et al. PubChem's BioAssay Database. Nucleic Acids Res. 40, D400-D412 (2012).
45. Pouliot, Y., Chiang, A.P. & Butte, A.J. Predicting adverse drug reactions using publicly available PubChem BioAssay data. Clin. Pharmacol. Ther. 90, 90-99 (2011).
46. Kinnings, S.L., Liu, N., Buchmeier, N., Tonge, P.J., Xie, L. & Bourne, P.E. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput. Biol. 5, e1000423 (2009).
47. Keiser, M.J., Roth, B.L., Armbruster, B.N., Ernsberger, P., Irwin, J.J. & Shoichet, B.K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206 (2007).
48. Lounkine, E. et al. Large-scale prediction and testing of drug activity on sideeffect targets. Nature 486, 361-367 (2012).
49. Keiser, M.J. et al. Predicting new molecular targets for known drugs. Nature 462, 175-181 (2009).
50. Kitchen, D.B., Decornez, H., Furr, J.R. & Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3, 935-949 (2004).
51. DesJarlais, R.L. et al. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. USA 87, 6644-6648 (1990).
52. Grubb, S.C., Maddatu, T.P., Bult, C.J. & Bogue, M.A. Mouse phenome database. Nucleic Acids Res. 37, D720-D730 (2009).
53. Coombes, R. GlaxoSmithKline grants researchers access to clinical trial data. BMJ 345, e6909 (2012).
54. Jensen, P.B., Jensen, L.J. & Brunak, S. Mining electronic health records: towards better research applications and clinical care. Nat. Rev. Genet. 13, 395-405 (2012).
55. Wicks, P., Vaughan, T.E., Massagli, M.P. & Heywood, J. Accelerated clinical discovery using self-reported patient data collected online and a patientmatching algorithm. Nat. Biotechnol. 29, 411-414 (2011).
56. Benton, A. et al. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J. Biomed. Inform. 44, 989-996 (2011).
57. Harpaz, R., DuMouchel, W., Shah, N.H., Madigan, D., Ryan, P. & Friedman, C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 91, 1010-1021 (2012).
58. Tatonetti, N.P., Ye, P.P., Daneshjou, R. & Altman, R.B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 4, 125ra31 (2012).
59. Allison, M. NCATS launches drug repurposing program. Nat. Biotechnol. 30, 571-572 (2012).
60. Lee, J.A. et al. Open innovation for phenotypic drug discovery: The PD2 assay panel. J. Biomol. Screen. 16, 588-602 (2011).
61. Huang, R. et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3, 80ps16 (2011).
62. Lesko, L.J. Drug research and translational bioinformatics. Clin. Pharmacol. Ther. 91, 960-962 (2012).
63. Butte, A.J. Translational bioinformatics: coming of age. J. Am. Med. Inform. Assoc. 15, 709-714 (2008).
64. Altman, R.B. Translational bioinformatics: linking the molecular world to the clinical world. Clin. Pharmacol. Ther. 91, 994-1000 (2012).